Advances in the use of angiogenesis inhibitors in cancer.
Pinedo
H M
HM
Department of Medical Oncology, University Hospital, Vrije Universiteit, Amsterdam, The Netherlands.
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005346:Fibroblast Growth Factors / Q000378:metabolism; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D008222:Lymphokines / Q000037:antagonists & inhibitors / Q000378:metabolism; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D000078183:Oxindoles; D010982:Platelet-Derived Growth Factor / Q000378:metabolism; D011422:Propionates; D011758:Pyrroles / Q000627:therapeutic use; D017978:Receptors, Growth Factor / Q000037:antagonists & inhibitors; D015291:Transforming Growth Factors / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D016228:Endothelial Growth Factors; D004791:Enzyme Inhibitors; D007211:Indoles; D008222:Lymphokines; D000078183:Oxindoles; D010982:Platelet-Derived Growth Factor; D011422:Propionates; D011758:Pyrroles; D017978:Receptors, Growth Factor; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D005346:Fibroblast Growth Factors; C116890:Semaxinib; D015291:Transforming Growth Factors; C412603:orantinib